Full-Time
Position Management Expert
Confirmed live in the last 24 hours
Sanofi
10,001+ employees
Develops pharmaceuticals and vaccines globally
No salary listed
Expert
Hyderabad, Telangana, India
- Bachelor’s degree in Business Administration, Information Technology, Human Resources, or a related field; advanced degree preferred.
- 10 years of experience managing Workday core HCM, with a focus on position management
- Minimum of 5 years of experience in data management, HRIS, or related fields
- Strong technical and configurational expertise in Workday, including proficiency in OrgStudio and other relevant tools
- Workday HCM Pro certification is required
- Strong analytical and problem-solving skills, with the ability to interpret data and solve complex problems
- Excellent verbal and written communication skills, capable of conveying technical concepts to non-technical stakeholders
- Strong interpersonal skills, with the ability to build relationships and work effectively within cross-functional teams.
- Manage and maintain all position management governance within Workday, including and align to complex business needs
- Configure Cost Center and Company Hierarchy’s in Workday for non-integrated ERP systems
- Identifies, communicates and executes Continuous Improvement plan for the Position Management Data
- Lead, Implement and Govern large scale Company reorganization activities related to acquisitions, divestitures, or internal restructuring initiatives in Workday
- Collaborate with cross-functional teams, including HR, Finance, and IT, to provide guidance on Workday data management best practices
- Ensure compliance with data governance policies and standards
- Drive continuous improvement initiatives for position management processes and data quality
- Develop and maintain documentation for position management processes and procedures
- Act as Level 3 expert and provide expert-level support for organization-related issues and inquiries
- Knowledge management through the team and the development of HRS to ensure a high level of support (documentation, knowledge sharing…), contribution to knowledge transfer and education of first and second levels of support (Employee Contact Center, P&C Partners, HR Data Management teams…).
Sanofi provides healthcare solutions through its pharmaceutical and biotechnology products, focusing on treatments and vaccines for various medical conditions. The company conducts extensive research and development to create new therapies and improve existing ones, particularly in areas like immunology, oncology, and rare diseases. Sanofi's products include prescription medicines, over-the-counter items, and vaccines, which are distributed to patients, healthcare professionals, and governments worldwide. What sets Sanofi apart from its competitors is its strong emphasis on scientific innovation and strategic partnerships, allowing it to maintain a diverse product pipeline and adapt to different regulatory environments. The company's goal is to enhance health outcomes and improve the quality of life for people globally.
Company Size
10,001+
Company Stage
IPO
Headquarters
Paris, France
Founded
1973
Simplify's Take
What believers are saying
- Sanofi reported a 20% profit growth in Q1 2025, driven by Dupixent and new launches.
- The FDA approved Dupixent for chronic spontaneous urticaria, expanding its treatment indications.
- Sanofi's investment in Innate Pharma supports its strategic goals in oncology.
What critics are saying
- Increased competition in immunology could impact Dupixent's market share.
- Potential delays in EU approval for tolebrutinib may affect market entry.
- The Dren Bio acquisition may not yield expected financial returns.
What makes Sanofi unique
- Sanofi's Dupixent is the first targeted therapy for chronic spontaneous urticaria.
- Tolebrutinib is a potential first-in-class therapy for non-relapsing secondary progressive multiple sclerosis.
- Sanofi's acquisition of Dren Bio enhances its biopharmaceutical capabilities.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Health Insurance
Professional Development Budget
Parental Leave
Company News
Innate Pharma announced a €15M investment by Sanofi, subscribing to 8,345,387 new shares at €1.7974 each. This capital increase supports their ongoing partnership, including the BCMA targeting ANKET® program. The investment will aid in extending Innate's cash runway for pipeline execution. The capital increase is expected to close on April 25, 2025, with shares trading on Euronext Paris the same day.
Sanofi SA (NASDAQ:SNY) reported Thursday a first-quarter 2025 business operating income of 2.9 billion euros ($3.06 billion), up 20.1% year over year and 18.7% in constant currency. The company reported first-quarter sales of 9.89 billion euros ($10.42 billion), beating the consensus of $9.77 billion. This was driven by launches, Dupixent, and favorable Beyfortus phasing. Sales increased 10.8% year over year and 9.7% on constant currency. U.S. sales were 4.66 billion and increased by 15.4%
Dupixent approved in the US as the first new targeted therapy in over a decade for chronic spontaneous urticariaApproval based on phase 3 studies demonstrating Dupixent significantly reduced itch and hives compared to placeboIn the US, there are more than 300,000 adults and adolescents aged 12 years and older living with CSU who remain symptomatic despite antihistamine treatmentCSU is the seventh disease with underlying type 2 inflammation in which Dupixent is approvedParis and Tarrytown, NY, April 18, 2025. The US Food and Drug Administration (FDA) has approved Dupixent (dupilumab) for the treatment of adults and adolescents aged 12 years and older with chronic spontaneous urticaria (CSU) who remain symptomatic despite histamine-1 (H1) antihistamine treatment.Kenneth MendezPresident and Chief Executive Officer at the Asthma and Allergy Foundation of America“People with chronic spontaneous urticaria experience sudden, unpredictable hives and severe itch that cause a significant, and often overwhelming, burden on their everyday lives. The approval of this treatment offers patients more options and the chance to control their disease.”Alyssa Johnsen, M.D., Ph.D.Global Therapeutic Area Head, Immunology and Oncology Development at Sanofi“CSU patients with uncontrolled disease experience highly burdensome itch and hives that can significantly disrupt daily living. This FDA approval provides a new treatment option to help address the underlying drivers of these severe and recurring signs and symptoms. Dupixent has the potential to improve outcomes for CSU patients who previously had limited treatment options.”The US approval is based on data from two phase 3 clinical studies, Study A (n=136) and Study C (n=148), which included biologic-naïve patients aged 12 years and older who were symptomatic despite the use of antihistamines and assessed Dupixent as an add-on therapy to standard-of-care antihistamines, compared to antihistamines alone. Both studies met their primary and key secondary endpoints with Dupixent demonstrating reductions in itch severity and urticaria activity (a composite of itch and hives) compared to placebo at 24 weeks
Results from the HERCULES phase 3 study showed delay in disability progression in people living with non-relapsing secondary progressive multiple sclerosisTolebrutinib has the potential to be the first therapy to modulate immunologic drivers of chronic inflammation behind the blood–brain barrier, a key driver of disability accumulation in MSTolebrutinib is being evaluated under priority review in the US with a target action date of 28 September 2025; regulatory submission dossier is under review in the EU with a decision expected in Q1 2026Paris, April 8, 2025. The New England Journal of Medicine (NEJM) published positive results from the HERCULES phase 3 study demonstrating that tolebrutinib delayed disability progression in people with non-relapsing secondary progressive multiple sclerosis (nrSPMS), where there are currently no treatment options approved. These findings further support the differentiated mechanism of oral, brain-penetrant tolebrutinib, targeting disability progression independent of relapse activity. These results were first presented at the ECTRIMS conference on September 20, 2024 in Copenhagen, Denmark and further analyses were also presented today during the Clinical Trials Plenary Session at the 2025 Annual Meeting for the American Academy of Neurology (AAN) in San Diego, California.Robert Fox, MDVice Chair of Research at Cleveland Clinic’s Neurological Institute, Cleveland, Ohio, US, and chair of the HERCULES global steering committee“Tolebrutinib represents a new class of therapy for the treatment of multiple sclerosis. In this large phase 3 study, tolebrutinib was found to slow the progression of disability in a subset of multiple sclerosis for which we have no approved therapies – non-relapsing secondary progressive disease. The results of this study signal a new chapter in multiple sclerosis because we finally found a potential way to treat non-relapsing secondary progressive forms.”Dr Fox is a paid advisor to Sanofi for the HERCULES study.Erik Wallström, MD, PhDGlobal Head of Neurology Development“By targeting disability progression mechanisms behind the blood-brain barrier, tolebrutinib has the potential to be a practice-changing therapeutic option for people living with multiple sclerosis
Paris, France – March 24, 2025. Sanofi announced today that its Q1 2025 Aide mémoire is available on the "Investors" page of the company's website:First quarter 2025 (sanofi.com)As for each quarter, Sanofi prepared this document to assist in the financial modelling of the Group's quarterly results. This document includes a reminder on various non-comparable items and exclusivity losses as well as the foreign currency impact and share count. Sanofi's first quarter 2025 results will be published on April 24, 2025.About SanofiWe are an innovative global healthcare company, driven by one purpose: we chase the miracles of science to improve people’s lives. Our team, across some 100 countries, is dedicated to transforming the practice of medicine by working to turn the impossible into the possible. We provide potentially life-changing treatment options and life-saving vaccine protection to millions of people globally, while putting sustainability and social responsibility at the center of our ambitions.Sanofi is listed on EURONEXT: SAN and NASDAQ: SNYMedia RelationsSandrine Guendoul | + 33 6 25 09 14 25 | [email protected] Berland | + 1 215 432 0234 | [email protected] Obrist | + 33 6 77 21 27 55 | [email protected]éo Le Bourhis | + 33 6 75 06 43 81 | [email protected] Rouault | + 33 6 70 93 71 40 | [email protected] Gilbert | + 1 516 521 2929 | [email protected] RelationsThomas Kudsk Larsen | + 44 75 45 51 36 93| [email protected]é Kaisserian | + 33 6 47 04 12 11 | [email protected] Lauscher | + 1 908 612 7239 | [email protected] Browne | +1 781 249 1766 | [email protected] Pham | + 33 7 85 93 30 17 | [email protected] Elgoutni | + 1 617 710 3587 | [email protected] Châtelet | + 33 6 80 80 89 90 | [email protected] Li | + 33 6 84 00 90 72 | [email protected] statementsThis press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended